Seasonal PrEP for partners of migrant miners in southern Mozambique: A highly focused PrEP intervention

Journal of the International AIDS Society

Volumn 18, Issue , 2015, Pages

  Cremin, Ide ^a   Morales, Fernando ^b   Jewell, Britta L ^a   O'Reilly, Kevin R ^c   Hallett, Timothy B ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

ARV based prevention; Cost effectiveness; HIV; Mathematical models; Pre exposure prophylaxis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CIRCUMCISION; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; HEALTH CARE COST; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MIGRANT; MIGRATION; MINER; MINING; MOZAMBIQUE; PATIENT COMPLIANCE; PRE-EXPOSURE PROPHYLAXIS; PREVALENCE; PRIORITY JOURNAL; REPRODUCTIVE HEALTH; SCALE UP; SEXUALITY; SOUTH AFRICA; ADULT; HIV INFECTIONS; SEASON; TRANSMISSION;

ADULT; ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; MALE; MINERS; MOZAMBIQUE; PRE-EXPOSURE PROPHYLAXIS; SEASONS; SEXUAL PARTNERS; TRANSIENTS AND MIGRANTS;

EID: 84938281298     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.18.4.19946     Document Type: Article

References (25)

1. Baeten JM, Grant R. Use of antiretrovirals for HIV prevention: what do we know and what don't we know? Curr HIV/AIDS Rep. 2013;10:142-51.
2. Celum C, Baeten JM. Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis. Antivir Ther. 2012;17:1483-93.
3. Hankins CA. Untangling the cost-effectiveness knot: who is oral antiretroviral HIV pre-exposure prophylaxis really for? Expert Rev Pharmacoecon Outcomes Res. 2014;14:167-70.
4. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med. 2013;10:e1001401.
5. Anderson SJ, Cherutich P, Kilonzo N, Cremin I, Fecht D, Kimanga D, et al. Maximising the effect of combination HIV prevention through prioritisation of the people and places in greatest need: a modelling study. Lancet. 2014;384:249-56.
6. Jones A, Cremin I, Abdullah F, Idoko J, Cherutich P, Kilonzo N, et al. Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination prevention. Lancet. 2014;384:272-9.
7. Foreit KF, Barreto AT, Noya PA, Nhatave I. Population movements and the spread of HIV/AIDS in Mozambique. J Health Hum Serv Adm. 2001;24:279-94.
8. Instituto Nacional de Saúde (INS), Instituto Nacional de Estatística (INE), e ICF Macro. Inquérito Nacional de Prevalência, Riscos Comportamentais e Informação sobre o HIV e SIDA em Moçambique 2009. Calverton, MD: INS; 2010.
9. Crush J, Raimundo I, Simwlane H, Cau B, Dorey D. Migration-induced HIV and AIDS in rural Mozambique and Swaziland. Migration Policy Series No. 53. The Southern African Migration Programme [Internet]. 2010 [cited 2014 Aug 11]. Available from: http://www.queensu.ca/samp/sampresources/samppublications/policyseries/Acrobat53.pdf
10. Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS. 2013;27:447-58.
11. MISAU, INS, CDC, UCSF, MITRAB, I-TECH. Final report: the integrated biological and behavioral survey among Mozambican workers in South African Mines, 2012. Maputo: MISAU; 2013.
12. Chemaitelly H, Shelton JD, Hallett TB, Abu-Raddad LJ. Only a fraction of new HIV infections occur within identifiable stable discordant couples in sub-Saharan Africa. AIDS. 2013;27:251-60.
13. Baggaley RF, White RG, Hollingsworth TD, Boily MC. Heterosexual HIV-1 infectiousness and antiretroviral use: systematic review of prospective studies of discordant couples. Epidemiology. 2013;24:110-21.
14. World Health Organization. Progress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa. Brazzaville, Republic of Congo: WHO; 2012.
15. Instituto Nacional de Estatística (INE), e IMinisterio da Saude (MISAU), MEASURE DHS+/ORC Macro. Moçambique Inquérito Demográfico e de Saúde 2003. Calverton, MD: INE, MISAU, e ORC Macro; 2005.
16. IMinisterio da Saude (MISAU), Instituto Nacional de Estatística (INE), e ICF International (ICFI). Moçambique Inquérito Demográfico e de Saúde 2011. Calverton, MD: MISAU, INE e ICFI; 2013.
17. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643-56.
18. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Krieger JN, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369:657-66.
19. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med. 2005;2:e298.
20. de Bruyn G, Magaret A, Baeten JM, Lingappa JR, Ndase P, Celum C, et al. Mortality in members of HIV-1 serodiscordant couples in Africa and implications for antiretroviral therapy initiation: results of analyses from a multicenter randomized trial. BMC Infect Dis. 2012;12:277.
21. Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66:340-8.
22. Menzies NA, Berruti AA, Blandford JM. The determinants of HIV treatment costs in resource limited settings. PLoS One. 2012;7:e48726.
23. Feldblum PJ, Enosse S, Dube K, Arnaldo P, Muluana C, Banze R, et al. HIV prevalence and incidence in a cohort of women at higher risk for HIV acquisition in Chokwe, southern Mozambique. PLoS One. 2014;9:e97547.
24. Garnett GP, Cousens S, Hallett TB, Steketee R, Walker N. Mathematical models in the evaluation of health programmes. Lancet. 2011;378:515-25.
25. Delva W, Wilson DP, Abu-Raddad L, Gorgens M, Wilson D, Hallett TB, et al. HIV treatment as prevention: principles of good HIV epidemiology modelling for public health decision-making in all modes of prevention and evaluation. PLoS Med. 2012;9:e1001239.